In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment
-- Studies show DBF, tentatively named Libervant™, was successfully administered and had similar bioavailability whether given during/immediately following a seizure or between seizures
Associations are now promoting relevant professional education to job seekers during online job searches through newly enhanced Crowd Wisdom LMS and YM Careers integration
- Phase 2 trial successfully reached predetermined response criteria in difficult to treat over 60, unfit patient population and demonstrated minimal extramedullary toxicities
The 3rd Annual Dental Business & Legal Symposium captured the attention of more than 280 dental professionals eager to learn efficient ways in growing their practice and continuing their education.
- Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients -
- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients
- Initial results were presented from ongoing Phase 1/2 trials in pediatric acute lymphoblastic leukemia (AMELIA trial) and diffuse B cell lymphoma (ALEXANDER trial) -